Biotech and Pharma are tearing up the market this year, and according to Ron Winslow writing in the Wall Street Journal, a powerful new class of drugs promises hope for high-risk patients with cholesterol issues—a group that numbers in the millions. Companies like Regeneron may be in the right place at the right time, up over 25% for the year. Is there room to run? Sinclair and Steve review what's happening. In the Q & A segment, CFP® Murray Titterington with IQ Wealth joins the A-Team to discuss Social Security taxation issues.